CAR T-Cell Therapy For Solid Tumors

In latest clinical trials, Chimeric antigen receptor (CAR) T cell therapy, which edits a cancer patient’s T cells to recognize their tumors, has dramatically improved the outcomes of blood cancer patients with advanced, otherwise untreatable forms of leukemia and lymphoma, but has yet to demonstrate the capability to treat solid tumors, the leading cause of cancer-related deaths, because they have targeted molecules found on the surface of both normal cells and cancer cells, resulting in serious side effects. Read More